In the news

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

The VAPEUR clinical trial compared Rezūm™ Water Vapor Therapy to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in sexually active men. Key findings from the study demonstrate that Rezūm Therapy provides superior BPH symptom relief versus combination therapy while preserving sexual function.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.